Drug Profile
Research programme: RNA-based therapeutics - Roche/Takeda
Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Santaris Pharma
- Developer Roche
- Class Antisense oligonucleotides
- Mechanism of Action Antisense RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in Denmark (Parenteral)
- 26 Aug 2013 Research is ongoing in Denmark